Literature DB >> 19118122

Modulation of excitatory synaptic transmission by Delta 9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate.

Alan M Roloff1, Stanley A Thayer.   

Abstract

Delta(9)-tetrahydrocannabinol (THC), the principal psychoactive ingredient in marijuana, acts as a partial agonist on presynaptic cannabinoid type 1 (CB1) receptors to inhibit neurotransmitter release. Here, we report that THC inhibits excitatory neurotransmission between cultured rat hippocampal neurons in a manner highly sensitive to stimulus rate. THC (1 microM) inhibited excitatory postsynaptic currents (EPSCs) and whole-cell I(Ca) evoked at 0.1 Hz but at 0.5 Hz THC had little effect. The cannabinoid receptor full agonists [(R)-(+)-[2,3-dihydro-5-methyl-3[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate salt] (Win55212-2) (100 nM) and 2-arachidonylglycerol (1 microM) inhibited EPSCs independent of stimulation at 0.1 or 0.5 Hz. THC occupied CB1 receptors at 0.5 Hz, but the receptors failed to couple to presynaptic Ca(2+) channels. Consequently, 1 microM THC blocked the inhibition of EPSC amplitude by Win55212-2 when EPSCs were evoked at 0.5 Hz. A depolarizing prepulse to 0 mV reversed THC inhibition of I(Ca), but reversal of the inhibition produced by Win55212-2 required a pulse to +80 mV, suggesting that the voltage-dependent reversal of Gbetagamma inhibition of voltage-gated Ca(2+) channels accounts for the frequency-dependence of cannabinoid action. THC blocked depolarization-induced suppression of EPSCs evoked at 0.5 Hz, indicating that it inhibited retrograde endocannabinoid signaling in a frequency-dependent manner. Thus, THC displayed a state-dependent switching from agonist to antagonist that may account for its complex actions in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19118122      PMCID: PMC2684930          DOI: 10.1124/mol.108.051482

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  Modulation of transmission during trains at a cerebellar synapse.

Authors:  A C Kreitzer; W G Regehr
Journal:  J Neurosci       Date:  2000-02-15       Impact factor: 6.167

2.  Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations.

Authors:  N Hájos; I Katona; S S Naiem; K MacKie; C Ledent; I Mody; T F Freund
Journal:  Eur J Neurosci       Date:  2000-09       Impact factor: 3.386

3.  Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition.

Authors:  C S Breivogel; S R Childers
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

4.  Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation.

Authors:  D E Selley; W K Rorrer; C S Breivogel; A M Zimmer; A Zimmer; B R Martin; L J Sim-Selley
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

5.  Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses.

Authors:  Takako Ohno-Shosaku; Hiroshi Tsubokawa; Ichiro Mizushima; Norihide Yoneda; Andreas Zimmer; Masanobu Kano
Journal:  J Neurosci       Date:  2002-05-15       Impact factor: 6.167

6.  Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture.

Authors:  Maria Kouznetsova; Brooke Kelley; Maoxing Shen; Stanley A Thayer
Journal:  Mol Pharmacol       Date:  2002-03       Impact factor: 4.436

7.  Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons.

Authors:  Juan Guo; Stephen R Ikeda
Journal:  Mol Pharmacol       Date:  2004-03       Impact factor: 4.436

8.  Custom distinctions in the interaction of G-protein beta subunits with N-type (CaV2.2) versus P/Q-type (CaV2.1) calcium channels.

Authors:  Heather L Agler; Jenafer Evans; Henry M Colecraft; David T Yue
Journal:  J Gen Physiol       Date:  2003-06       Impact factor: 4.086

9.  Activation of CB1 specifically located on GABAergic interneurons inhibits LTD in the lateral amygdala.

Authors:  Shahnaz Christina Azad; Jörg Kurz; Giovanni Marsicano; Beat Lutz; Walter Zieglgänsberger; Gerhard Rammes
Journal:  Learn Mem       Date:  2008-03-05       Impact factor: 2.460

10.  The endogenous cannabinoid system controls extinction of aversive memories.

Authors:  Giovanni Marsicano; Carsten T Wotjak; Shahnaz C Azad; Tiziana Bisogno; Gerhard Rammes; Maria Grazia Cascio; Heike Hermann; Jianrong Tang; Clementine Hofmann; Walter Zieglgänsberger; Vincenzo Di Marzo; Beat Lutz
Journal:  Nature       Date:  2002-08-01       Impact factor: 49.962

View more
  15 in total

1.  JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist.

Authors:  Brady K Atwood; John Huffman; Alex Straiker; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-01-22       Impact factor: 8.739

2.  Homer 1a gates the induction mechanism for endocannabinoid-mediated synaptic plasticity.

Authors:  Alan M Roloff; Garret R Anderson; Kirill A Martemyanov; Stanley A Thayer
Journal:  J Neurosci       Date:  2010-02-24       Impact factor: 6.167

3.  Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro.

Authors:  Anastasia Bologov; Mikhal Gafni; Ora Keren; Yosef Sarne
Journal:  Cell Mol Neurobiol       Date:  2010-11-04       Impact factor: 5.046

Review 4.  Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.

Authors:  C J Hillard; K M Weinlander; K L Stuhr
Journal:  Neuroscience       Date:  2011-11-17       Impact factor: 3.590

5.  Monoacylglycerol lipase inhibitor JZL184 prevents HIV-1 gp120-induced synapse loss by altering endocannabinoid signaling.

Authors:  Xinwen Zhang; Stanley A Thayer
Journal:  Neuropharmacology       Date:  2017-10-20       Impact factor: 5.250

Review 6.  The dual neuroprotective-neurotoxic profile of cannabinoid drugs.

Authors:  Yosef Sarne; Fadi Asaf; Miriam Fishbein; Mikhal Gafni; Ora Keren
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

7.  Cannabidiol inhibits synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways.

Authors:  C J Ledgerwood; S M Greenwood; R R Brett; J A Pratt; T J Bushell
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

8.  Delta9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus.

Authors:  Nora Laaris; Cameron H Good; Carl R Lupica
Journal:  Neuropharmacology       Date:  2010-04-22       Impact factor: 5.250

9.  Cannabinoid CB1 receptor-dependent long-term depression in autaptic excitatory neurons.

Authors:  Ryan Kellogg; Ken Mackie; Alex Straiker
Journal:  J Neurophysiol       Date:  2009-06-03       Impact factor: 2.714

10.  Electrophysiological Measurement of Cannabinoid-Mediated Synaptic Modulation in Acute Mouse Brain Slices.

Authors:  Rita Báldi; Dipanwita Ghosh; Brad A Grueter; Sachin Patel
Journal:  Curr Protoc Neurosci       Date:  2016-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.